Roche In-licenses Amunix’s Half-life Extension Technology in US$1.5 B Deal

By Sharath Chandra Nakka

Pharma Deals Review: Vol 2020 Issue 1 (Table of Contents)

Published: 28 Jan-2020

DOI: 10.3833/pdr.v2020.i1.2505     ISSN: 1756-7874

Section: Licensing



Building on its platform technology portfolio, Roche has entered into a technology licensing agreement with Amunix Pharmaceuticals for its half-life extension platform, XTEN®, to discover and develop novel therapeutics in non-oncology indications...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details